[Real-world study of tenofovir amibufenamide in the treatment of patients with hepatitis B cirrhosis].
Year: 2024
Type: other
Abstract: TMF antiviral therapies have an HBV DNA negative rate of over 80% at 12 months and can improve the liver function in patients with hepatitis B cirrhosis. However, there were no significant changes in renal function and blood lipids before and after treatment.
Source: PubMed
Authors: Y Han, A J Zeng, X Y Liang, Y N Liu, K K Jin, H G Ding
Institutions: Capital Medical University, Beijing YouAn Hospital
Language: English
Topic: Hepatitis B Virus Studies
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4407800813